TOL 463

Drug Profile

TOL 463

Alternative Names: TOL-463

Latest Information Update: 24 Aug 2016

Price : $50

At a glance

  • Originator Toltec Pharmaceuticals
  • Developer National Institute of Allergy and Infectious Diseases
  • Class Antibacterials; Antifungals; Antiseptics; Boric acids
  • Mechanism of Action Bacterial growth inhibitors; Cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Vaginitis

Most Recent Events

  • 01 Jul 2016 Phase-II clinical trials in Vaginitis in USA (Vaginal, Suppository) (NCT02866227)
  • 01 Jul 2016 Phase-II clinical trials in Vaginitis in USA (Vaginal, Gel) (NCT02866227)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top